Evidence map›Paper›PMID 36620536›Full record

ArticleFrontiers in oncology2022

The reduction of

Fengpeng Wu, Xiaoxiao Zhang, Congrong Yang, Kanghua Wang, Linlin Xiao, Chaoxi Zhou, Xinming Zhao, Guiying Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Fengpeng WuDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaoxiao ZhangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Congrong YangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Kanghua WangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Linlin XiaoDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chaoxi ZhouDepartment of General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xinming ZhaoDepartment of Nuclear Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Guiying WangDepartment of Radiation Oncology, Hebei Cancer Hospital Chinese Academy of Medical Sciences, Langfang, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CNSecond Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: To evaluate the predictive value of Methods: From January 2016 to March 2020, 52 LARC patients who underwent Results: Tumor response assessment showed that 13 of 52 patients received good response (GR), including 9 cases with pathological complete regression (pCR) and 4 cases with near-pathological complete regression (near-pCR). We also found that the maximum standard uptake value after nCRT (post-SUVmax), the response index (RI), the mean standard uptake values after nCRT (post-SUVmean), and the ratio of tumor SUVmean to liver SUVmean after nCRT (post-Ratio), were correlated with GR and pCR. Among these parameters, post-SUVmax and RI had a near-strong correlation with pCR (r Conclusion: For LARC patients, the analysis of imaging parameters such as post-SUVmax and RI, which can reflect the changes of

Indexed as

18F-FDG PET-CTclinical complete regressionlocally advanced rectal cancernear-pathological complete regressionneoadjuvant chemoradiotherapy (NACRT)pathological complete regression

Identifiers

PMID36620536
PMCPMC9814115
OpenAlexW4312187604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.